Xizang Haisco Pharmaceutical Group Co Ltd Working Capital to Net Assets Ratio
Xizang Haisco Pharmaceutical Group Co Ltd working capital to net assets ratio. Xizang Haisco Pharmaceutical Group Co Ltd (002653) has a Working Capital to Net Assets ratio of 25.0% as of June 2026. Working capital of CN¥1.21 Billion (current assets of CN¥3.46 Billion minus current liabilities of CN¥2.26 Billion) is measured against net assets of CN¥4.81 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Xizang Haisco Pharmaceutical Group Co Ltd (2008–2025)
Working capital to net assets ratio of Xizang Haisco Pharmaceutical Group Co Ltd from 2008 to 2025. This chart shows how Xizang Haisco Pharmaceutical Group Co Ltd's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2008 to 2025. As of June 2026, the ratio stands at 25.0%, reflecting working capital of CN¥1.21 Billion against net assets of CN¥4.81 Billion CNY. Explore how much of Xizang Haisco Pharmaceutical Group Co Lt's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Xizang Haisco Pharmaceutical Group Co Ltd Working Capital to Net Assets Ratio by Year (2008–2025)
Xizang Haisco Pharmaceutical Group Co Ltd working capital to net assets ratio by year from 2008 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Xizang Haisco Pharmaceutical Group Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 002653 total asset value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 29.5% | CN¥1.27 Billion | CN¥4.29 Billion | CN¥2.83 Billion | CN¥1.57 Billion | ▲ +1.9 pp |
| 2024 | 27.6% | CN¥1.16 Billion | CN¥4.20 Billion | CN¥2.73 Billion | CN¥1.57 Billion | ▲ +0.4 pp |
| 2023 | 27.3% | CN¥1.14 Billion | CN¥4.17 Billion | CN¥2.64 Billion | CN¥1.50 Billion | ▲ +9.2 pp |
| 2022 | 18.0% | CN¥565.09 Million | CN¥3.13 Billion | CN¥2.05 Billion | CN¥1.49 Billion | ▲ +17.0 pp |
| 2021 | 1.0% | CN¥30.32 Million | CN¥2.92 Billion | CN¥1.55 Billion | CN¥1.52 Billion | ▼ -12.2 pp |
| 2020 | 13.2% | CN¥377.83 Million | CN¥2.85 Billion | CN¥2.10 Billion | CN¥1.72 Billion | ▲ +31.0 pp |
| 2019 | -17.7% | CN¥-421.09 Million | CN¥2.38 Billion | CN¥2.08 Billion | CN¥2.50 Billion | ▼ -14.1 pp |
| 2018 | -3.6% | CN¥-71.87 Million | CN¥1.99 Billion | CN¥1.98 Billion | CN¥2.05 Billion | ▲ +7.6 pp |
| 2017 | -11.2% | CN¥-220.55 Million | CN¥1.97 Billion | CN¥1.81 Billion | CN¥2.03 Billion | ▼ -67.5 pp |
| 2016 | 56.3% | CN¥1.26 Billion | CN¥2.25 Billion | CN¥2.28 Billion | CN¥1.01 Billion | ▲ +38.0 pp |
| 2015 | 18.2% | CN¥393.35 Million | CN¥2.16 Billion | CN¥1.39 Billion | CN¥992.79 Million | ▼ -48.0 pp |
| 2014 | 66.2% | CN¥1.40 Billion | CN¥2.11 Billion | CN¥2.12 Billion | CN¥721.42 Million | ▲ +8.5 pp |
| 2013 | 57.7% | CN¥1.11 Billion | CN¥1.93 Billion | CN¥1.59 Billion | CN¥482.33 Million | ▼ -20.6 pp |
| 2012 | 78.3% | CN¥1.34 Billion | CN¥1.71 Billion | CN¥1.53 Billion | CN¥196.65 Million | ▲ +11.1 pp |
| 2011 | 67.2% | CN¥515.97 Million | CN¥767.76 Million | CN¥593.75 Million | CN¥77.78 Million | ▼ -0.7 pp |
| 2010 | 67.9% | CN¥307.71 Million | CN¥453.09 Million | CN¥431.35 Million | CN¥123.64 Million | ▲ +56.2 pp |
| 2009 | 11.7% | CN¥15.80 Million | CN¥135.17 Million | CN¥227.17 Million | CN¥211.37 Million | ▼ -44.1 pp |
| 2008 | 55.8% | CN¥119.88 Million | CN¥214.95 Million | CN¥252.07 Million | CN¥132.18 Million | — |